By Catherine Eckford2025-02-13T12:42:57
The directive could lead to nearly €1 billion in additional costs for pharmaceutical companies in Finland alone, states Orion Corporation.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-16T10:59:00Z
2026-06-15T07:55:00Z
Sponsored by Octave, By Adam Cross
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-06-15T07:55:00
Sponsored by Octave, By Adam Cross
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2026-06-16T13:00:00 2026-06-16T14:00:00
Sponsored by USP
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
Site powered by Webvision Cloud